Unicycive Therapeutics (UNCY) News Today → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free UNCY Stock Alerts $1.00 +0.03 (+3.10%) (As of 02:57 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUnicycive Therapeutics (NASDAQ:UNCY) Given "Speculative Buy" Rating at Benchmarkamericanbankingnews.com - April 16 at 3:34 AMBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioningmarkets.businessinsider.com - April 12 at 1:16 PMUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conferenceglobenewswire.com - April 10 at 7:03 AMUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDmarkets.businessinsider.com - April 4 at 4:58 PMBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footingmarkets.businessinsider.com - April 2 at 4:34 AMUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023investorplace.com - March 28 at 11:31 PMUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 28 at 8:12 PMUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 28 at 4:15 PMUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congressglobenewswire.com - March 25 at 7:03 AMUnicycive reports progress in kidney injury treatment trialinvesting.com - March 16 at 12:26 AMBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate Prospectsmarkets.businessinsider.com - March 14 at 3:38 PMUnicycive Announces $50 Million Private Placementglobenewswire.com - March 14 at 7:03 AMUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conferenceglobenewswire.com - March 13 at 7:03 AMUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 64.3% in Februarymarketbeat.com - March 12 at 1:43 PMUnicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)finanznachrichten.de - March 9 at 1:24 AMUnicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)globenewswire.com - March 7 at 4:12 PMBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug Designationmarkets.businessinsider.com - March 6 at 4:12 PMUnicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from HC Wainwrightmarketbeat.com - March 5 at 8:17 AMUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patientsglobenewswire.com - March 4 at 7:03 AMShort Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Grows By 46.7%marketbeat.com - March 1 at 9:47 AMUnicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest Reportbenzinga.com - February 25 at 9:25 AMUnicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 25 at 9:25 AMUnicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46msn.com - February 24 at 11:54 PMUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meetingfinance.yahoo.com - February 14 at 9:33 AMUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meetingglobenewswire.com - February 14 at 7:03 AMWe're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Ratefinance.yahoo.com - February 6 at 8:24 AMUnicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conferencefinance.yahoo.com - January 29 at 8:42 AMUnicycive (UNCY) Up on Positive Hyperphosphatemia Study Updatefinance.yahoo.com - January 24 at 11:10 AMUnicycive Therapeutics, Inc.: Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestonesfinanznachrichten.de - January 23 at 9:41 AMUnicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestonesfinance.yahoo.com - January 23 at 9:41 AMUnicycive Therapeutics Stock (NASDAQ:UNCY), Guidance and Forecastbenzinga.com - December 21 at 9:26 AMUnicycive Therapeutics Stock (NASDAQ:UNCY) Dividends: History, Yield and Datesbenzinga.com - December 21 at 9:26 AMBuy Rating for Unicycive Therapeutics Backed by Strategic Advancements and Market Potentialmarkets.businessinsider.com - December 20 at 7:07 AMStrong Buy Rating for Unicycive Therapeutics Amidst Clinical Advances and Positive Valuation Outlookmarkets.businessinsider.com - December 19 at 9:06 PMUnicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysisfinance.yahoo.com - December 18 at 8:58 AMUnicycive Therapeutics to Participate in Two Investor Conferences in December 2023finance.yahoo.com - November 29 at 12:12 PMUnicycive Therapeutics, Inc.: Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 18 at 9:57 AMUnicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)finance.yahoo.com - November 17 at 8:21 AMAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Icecure Medical (ICCM) and Unicycive Therapeutics (UNCY)markets.businessinsider.com - November 16 at 7:42 PMUnicycive Announces Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 14 at 8:37 PMFDA, Unicycive Agree On Path To File NDA For Oxylanthanum Carbonatemarkets.businessinsider.com - October 23 at 12:05 PMUnicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)finance.yahoo.com - October 23 at 12:05 PMUnicycive Therapeutics, Inc.: Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhDfinanznachrichten.de - September 6 at 7:23 PMUnicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhDfinance.yahoo.com - September 6 at 7:24 AMUnicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Seriesfinance.yahoo.com - August 29 at 8:03 AMWill Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?finance.yahoo.com - August 17 at 7:28 AMWhere Unicycive Therapeutics Stands With Analystsmarkets.businessinsider.com - August 16 at 9:27 PMAnalysts Offer Insights on Healthcare Companies: Unicycive Therapeutics (UNCY), Legend Biotech (LEGN) and Reviva Pharmaceuticals Holdings (RVPH)markets.businessinsider.com - August 16 at 6:57 AMUnicycive Therapeutics, Inc.: Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - August 15 at 10:29 AMUnicycive Announces Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 10:37 PM Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. UNCY Media Mentions By Week UNCY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼-1.000.33▲Average Medical News Sentiment UNCY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼11▲UNCY Articles Average Week Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Marker Therapeutics News Cara Therapeutics News Eledon Pharmaceuticals News Clene News ProMIS Neurosciences News NRx Pharmaceuticals News BriaCell Therapeutics News Ocuphire Pharma News Rockwell Medical News Bolt Biotherapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
